



(51) International Patent Classification:

C07D 471/10 (2006.01) **A61P 25/24** (2006.01)
C07D 498/20 (2006.01) **A61P 29/00** (2006.01)
A61P 25/22 (2006.01)

(21) International Application Number:

PCT/EP2009/055190

(22) International Filing Date:

29 April 2009 (29.04.2009)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

0808030.1 1 May 2008 (01.05.2008) GB

(71) **Applicant** (for all designated States except US): **GLAXO
WELLCOME MANUFACTURING PTE LTD**
 [SG/SG]; 1 Pioneer Sector 1, Jurong, 628413 (SG).

(72) Inventors; and

(75) **Inventors/Applicants** (for US only): **ALVARO,
Giuseppe** [IT/IT]; GlaxoSmithKline, via Alessandro
 Fleming 2, I-37135 Verona (IT). **CASTIGLIONI, Emil-
iano** [IT/IT]; GlaxoSmithKline, via Alessandro Fleming
 2, I-37135 Verona (IT). **MARASCO, Agostino** [IT/IT];
 GlaxoSmithKline, via Alessandro Fleming 2, I-37135
 Verona (IT).

(74) **Agents:** **PEZZOLI, Anna** et al.; GlaxoSmithKline, Cor-
 porate Intellectual Property CN925.1, 980 Great West
 Road, Brentford Middlesex TW8 9GS (GB).

(81) **Designated States** (unless otherwise indicated, for every
 kind of national protection available): AE, AG, AL, AM,
 AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
 CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ,
 EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
 HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
 KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
 MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
 NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG,
 SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA,
 UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every
 kind of regional protection available): ARIPO (BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
 ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ,
 TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
 ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
 MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR),
 OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
 MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted
 a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of
 the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))

(54) **Title:** SPIRO (PIPERIDINE-4, 2'-PYRROLIDINE) -1- (3, 5- TRIFLUOROMETHYL PHENYL) METHYLCARBOXAM-
 IDES AS NK1 TACHIKYNIN RECEPTOR ANTAGONISTS



(I)

(57) **Abstract:** Compounds of formula (I) or a pharmaceutically acceptable salt thereof wherein R is hydrogen or C₁₋₄ alkyl; R₁ is hydrogen, C₁₋₄ alkyl, C(O)OH, C(O)NH₂ or (C₁₋₄ alkylene)R₁₀; R₂ and R₃ are independently hydrogen, C₁₋₄ alkyl or R₂ together with R₃ and together with the carbon atom to which they are attached form a C₃₋₈ cycloalkyl group; R₄ is C₁₋₄ alkyl, C₁₋₄ alkoxy or halogen; R₅ and R₇ are independently hydrogen, hydroxy, halogen, C(O)NH₂, C(O)OH or (C₁₋₄ alkylene) R₁₀; R₆ and R₈ are independently hydrogen or halogen; R₉ is hydrogen, (C₁₋₄ alkylene)R₁₀, C(O)NH₂, C(O)OH or R₉ together with R form a 6 membered heterocyclic ring optionally containing a further heteroatom selected from oxygen, sulphur or nitrogen; R₁₀ is hydrogen, halogen, hydroxy, C(O)NH₂, C(O)NH(C₁₋₄ alkyl), C(O)N(C₁₋₄ alkyl)₂ or C(O)OH; n is 0, 1 or 2. processes for their preparation, to compositions containing them and to their use in the treatment of diseases and conditions for which antagonism of NK1 is beneficial.